JP2019530440A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530440A5
JP2019530440A5 JP2019512186A JP2019512186A JP2019530440A5 JP 2019530440 A5 JP2019530440 A5 JP 2019530440A5 JP 2019512186 A JP2019512186 A JP 2019512186A JP 2019512186 A JP2019512186 A JP 2019512186A JP 2019530440 A5 JP2019530440 A5 JP 2019530440A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
chain variable
variable region
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055281 external-priority patent/WO2018042385A2/en
Publication of JP2019530440A publication Critical patent/JP2019530440A/ja
Publication of JP2019530440A5 publication Critical patent/JP2019530440A5/ja
Withdrawn legal-status Critical Current

Links

JP2019512186A 2016-09-02 2017-09-01 インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 Withdrawn JP2019530440A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662383237P 2016-09-02 2016-09-02
US62/383,237 2016-09-02
US201662440991P 2016-12-30 2016-12-30
US62/440,991 2016-12-30
US201762443509P 2017-01-06 2017-01-06
US62/443,509 2017-01-06
PCT/IB2017/055281 WO2018042385A2 (en) 2016-09-02 2017-09-01 Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments

Publications (2)

Publication Number Publication Date
JP2019530440A JP2019530440A (ja) 2019-10-24
JP2019530440A5 true JP2019530440A5 (enExample) 2020-10-08

Family

ID=61300216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512186A Withdrawn JP2019530440A (ja) 2016-09-02 2017-09-01 インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物

Country Status (8)

Country Link
US (2) US11701384B2 (enExample)
EP (1) EP3506943B1 (enExample)
JP (1) JP2019530440A (enExample)
KR (1) KR20190057308A (enExample)
CN (1) CN109963590B (enExample)
AU (1) AU2017319702B2 (enExample)
CA (1) CA3039136A1 (enExample)
WO (1) WO2018042385A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3765154A4 (en) 2018-03-14 2021-11-24 Celledit LLC MODIFICATION OF IMMUNE CELLS TO REDUCE TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
JP7314161B2 (ja) * 2018-03-14 2023-07-25 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法
KR20210070331A (ko) 2018-10-05 2021-06-14 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막 제거를 위한 hmgb1 단백질 유도체
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
WO2020243479A1 (en) 2019-05-31 2020-12-03 The Johns Hopkins University Bispecific binding agents
US20220251222A1 (en) * 2019-05-31 2022-08-11 The Johns Hopkins University IL-6Ralpha/IL-8R BISPECIFIC BINDING AGENTS FOR INHIBITING CANCER CELL MIGRATION
CA3145385A1 (en) * 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
US20250381272A1 (en) * 2022-06-22 2025-12-18 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5138941A (en) 1991-06-28 1992-08-18 Strauss Frederick J Wooden crusher for recyclable metal cans
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
BR9306802A (pt) 1992-07-27 1998-12-08 Pioneer Hi Bred Int Processo independente de genótipos para produção de planta de soja transgénica e processo de regeneração de plantas de soja a partir de nodos cotiledonais
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
JP2002510968A (ja) * 1997-05-07 2002-04-09 ブリストル−マイヤーズ スクイブ カンパニー 組換え抗体−酵素融合タンパク質
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7066469B2 (en) 2002-08-06 2006-06-27 University of Kentucky Research Foundation Board of Supervisors of Louisiana State University Seal assembly for machinery housing
US20040043949A1 (en) 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004085611A2 (en) 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
CN100509847C (zh) 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2006046661A1 (ja) * 2004-10-28 2006-05-04 Osaka University インターロイキン－６阻害剤
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP3520815B1 (en) 2005-02-08 2021-11-17 Genzyme Corporation Antibodies to tgfbeta
US20090068158A1 (en) 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
BRPI0619966A2 (pt) 2005-12-16 2011-10-25 Alcon Inc controle de pressão intra-ocular usando agentes de modulação de alk5
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8969082B2 (en) 2009-06-26 2015-03-03 Sea Lane Biotechnologies, Llc Expression of surrogate light chains
WO2011140170A1 (en) * 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP2904004B1 (en) 2012-10-04 2018-11-21 Research Development Foundation Serine protease molecules and therapies
EP2730289A1 (en) 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
AU2013347962B2 (en) 2012-11-21 2018-10-25 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
BR112015021595A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
US10836998B2 (en) 2014-02-14 2020-11-17 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2015128653A2 (en) 2014-02-27 2015-09-03 Ucl Business Plc Ligand
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
SMT201900596T1 (it) 2014-12-12 2019-11-13 Bluebird Bio Inc Recettori chimerici di antigene per bcma
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
JP7208010B2 (ja) * 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018102795A2 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
EP3641768B1 (en) 2017-06-21 2025-12-31 iCell Gene Therapeutics LLC Chimeric Antigen Receptors (CARs), Compositions and Associated Methods

Similar Documents

Publication Publication Date Title
JP2019530440A5 (enExample)
CN110662560B (zh) 改进的抗原结合受体
JP7115758B2 (ja) Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
JP7215997B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
RU2729401C2 (ru) Композиции и способы для иммунотерапии
JP2017531427A5 (enExample)
CN105189562B (zh) Il-15异源二聚体蛋白及其用途
JP2020508329A5 (enExample)
CN108697736A (zh) 治疗性组合物和方法
CN110461357A (zh) 抗cd16a抗体与细胞因子的组合
JP2019511222A5 (enExample)
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
JP2016505635A5 (enExample)
JP2018517431A (ja) 三重特異性結合タンパク質と使用方法
CN108463239A (zh) 白介素-15超激动剂显著提升移植物抗肿瘤活性
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2016529229A5 (enExample)
JP7404279B2 (ja) 様々な構築物最適化を備えたｔ細胞抗原カプラ
JP2017536337A5 (enExample)
TW202221021A (zh) 改良之抗原結合受體
KR102910876B1 (ko) 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제
JP2018505893A5 (enExample)
CN113056283A (zh) 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
US20230303660A1 (en) Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation